Greg Freiherr, Industry Consultant

Greg Freiherr has reported on developments in radiology since 1983. He runs the consulting service, The Freiherr Group.

Blog | Greg Freiherr, Industry Consultant | April 10, 2013

The New Age of Personalized Medicine

PET/CT helps bring personalized medicine within reach of practitioners. (Image courtesy of GE Healthcare)

We are seeing a semantic shift in medicine, one that is redefining personalized medicine from pie in the sky to piece of cake, undoable to doable. This redefinition uses tools within our grasp rather than tomorrow’s genomic machinations to individualize the assessment of disease risk, find its occurrence and refine treatment.

This shift is huge. It is not only ushering in a new present for medicine, but broadening the tools for making it work. Those in radiology today and in the future will comprise some of the best to personalize healthcare. They will grow in importance in the years ahead as research uncovers more of the biological changes and disease indicators that molecular imaging can target. 

It’s hard to say when — or even whether — these efforts will rise to the hype generated in the late-1990s that surrounded the decoding of the human genome. With its many pieces in place, the genomic puzzle was supposed to draw back the curtains on human vulnerability, revealing the differences among individuals that explained why one person developed cancer, for example, while another did not. These developments would be upstaged by explanations of why some patients respond well to treatments when others do not, providing the means to fine-tune the diagnostic and therapeutic to best manage patients — or even fix the faults in the genetic machinery to prevent some diseases altogether.

Despite more than a decade of looking, however, physicians still do not see the genetic chinks that form in the human armor against disease, much less the tactics for straightening out dysfunctional genetic materials to prevent diseases. Research is, however, uncovering more of the biological bits and pieces associated with early disease.

Evolving these biomarkers into targets for molecular imaging is beginning to provide the means to verify disease processes early in their development. They are also showing promise as the means to monitor the impact of therapy, as well as the recurrence of these processes after therapy has initially succeeded.

Moreover, advances in molecular imaging scanners are providing the means to more precisely visualize and even quantify these processes. As research continues into the genes that may form the soft underbelly of human disease, new and more specific biomarkers will emerge. These will translate inevitably into more personalized healthcare with tailored solutions occurring in a radiological spotlight cast by molecular imaging.

But meeting these technological challenges is not sufficient. It must be accompanied by advances in education to ensure that newly developed capabilities in personalized medicine are integrated into the practice of medicine. Clinical guidelines must become living documents that go beyond diagnosis and treatment to prediction and disease monitoring. And reimbursement, the engine of adoption, must expand to cover practices not now in use.

Related Content

New U.S. Tariffs on Chinese Goods Include Imaging Equipment
News | Radiology Business | June 15, 2018 | Jeff Zagoudis, Associate Editor
The Office of the U.S. Trade Representative (USTR) released the much-anticipated list of Chinese-manufactured goods...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Geraldine McGinty Elected First Female Chair of American College of Radiology

Image courtesy of the American College of Radiology

News | Radiology Business | May 22, 2018
The American College of Radiology (ACR) Board of Chancellors has elected Geraldine McGinty, M.D., MBA, FACR, as chair....
Joint ACR-SIIM Summit to Examine Economics of AI in Healthcare
News | Artificial Intelligence | May 15, 2018
On May 30, 2018, the American College of Radiology (ACR) Data Science Institute (DSI) and the Society for Imaging...
Charles E. Kahn Jr., M.D., M.S., will become editor of the new online journal, Radiology: Artificial Intelligence

Charles E. Kahn Jr., M.D., M.S.

News | Artificial Intelligence | May 02, 2018
The Board of Directors of the Radiological Society of North America (RSNA) announced that Charles E. Kahn Jr., M.D., M....
The Chalk River nuclear reactor license has been renewed, but will be decommissioned by 2028.

The Chalk River nuclear isotope reactor license has been renewed, but will be decommissioned by 2028. The reactor supplies about 50 percent of the world's supply of Tc99m.

Feature | Nuclear Imaging | April 02, 2018 | Dave Fornell
April 2, 2018 – The Canadian Nuclear Safety Commission (CNSC) announced March 29 that it renewed Canadian Nuclear Lab
What is the cost of interrupting a radiologist?
News | Clinical Study | March 20, 2018
March 20, 2018 – A first of its kind study...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
Sponsored Content | Case Study | Radiology Imaging | March 06, 2018
As one of the largest Catholic, not-for-profit healthcare systems in the United States, St. Louis-based SSM Health has...
ECR 2018 Spotlights Artificial Intelligence and Current Radiology Trends
News | Interventional Radiology | February 21, 2018
The European Congress of Radiology (ECR) announced the theme of its 2018 annual meeting, Feb. 28-March 4 in Vienna...
Overlay Init